<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00892</drugbank-id>
  <drugbank-id>APRD00817</drugbank-id>
  <name>Oxybuprocaine</name>
  <description>Oxybuprocaine is the name of a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions.</description>
  <cas-number>99-43-4</cas-number>
  <unii>AXQ0JYM303</unii>
  <average-mass>308.4158</average-mass>
  <monoisotopic-mass>308.209992772</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Katsuyuki Inoo, Mitsuhiro Kawada, Kenjiro Mori, "Oxybuprocaine-Containing Analgesic/Antipruritic External Preparation." U.S. Patent US20110124727, issued May 26, 2011.</synthesis-reference>
  <indication>Used to temporarily numb the front surface of the eye so that the eye pressure can be measured or a foreign body removed.</indication>
  <pharmacodynamics>Oxybuprocaine is a local anaesthetic. It may be less irritating than tetracaine, and the onset and duration of action are similar to tetracaine.</pharmacodynamics>
  <mechanism-of-action>Oxybuprocaine binds to sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.</description>
    <direct-parent>Benzoic acid esters</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzoic acids and derivatives</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Aminobenzoic acids and derivatives</alternative-parent>
    <alternative-parent>Aminophenyl ethers</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aminobenzoic acid or derivatives</substituent>
    <substituent>Aminophenyl ether</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Benzoate ester</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Ether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000226</drugbank-id>
      <name>Oxybuprocaine hydrochloride</name>
      <unii>0VE4U49K15</unii>
      <cas-number>5987-82-6</cas-number>
      <inchikey>PRGUDWLMFLCODA-UHFFFAOYSA-N</inchikey>
      <average-mass>344.877</average-mass>
      <monoisotopic-mass>344.186670511</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid</synonym>
    <synonym language="english" coder="">4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester</synonym>
    <synonym language="german" coder="">4-Amino-3-n-butoxy-benzoesäure-diäthylaminoäthylester</synonym>
    <synonym language="english" coder="">Benoxinate</synonym>
    <synonym language="english" coder="">BNX</synonym>
    <synonym language="english" coder="">Butoxyaminobenzoyldiethylaminoethanol</synonym>
    <synonym language="spanish" coder="inn">Oxibuprocaina</synonym>
    <synonym language="english" coder="">Oxybucaine</synonym>
    <synonym language="english" coder="inn">Oxybuprocaine</synonym>
    <synonym language="latin" coder="inn">Oxybuprocainum</synonym>
    <synonym language="english" coder="">Oxyriprocaine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Altafluor</name>
      <labeller>Altaire Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59390-206</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Altafluor</name>
      <labeller>Altaire Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59390-218</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number>NDA208582</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorescein Sodium &amp; Benoxinate Hydrochloride Ophthalmic Solution, USP</name>
      <labeller>Bausch &amp; Lomb Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237775</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluorescein Sodium and Benoxinate Hydrochloride</name>
      <labeller>Bausch &amp; Lomb Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code>24208-732</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluorox</name>
      <labeller>White Ophthalmic Services &amp; Supply Co Ltd</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02354993</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-28</started-marketing-on>
      <ended-marketing-on>2013-08-19</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluress</name>
      <labeller>Akorn, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>17478-640</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-02-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fluress</name>
      <labeller>Akorn Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02216728</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Fluress Liq Oph</name>
      <labeller>Pilkington Barnes Hind</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02053772</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1969-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-14</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Flurox</name>
      <labeller>O Cu Soft, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54799-506</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-08-30</started-marketing-on>
      <ended-marketing-on>2012-02-29</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flurox</name>
      <labeller>OCuSOFT, INC.</labeller>
      <ndc-id/>
      <ndc-product-code>54799-508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Minims Benoxinate Hydrochloride 0.4%</name>
      <labeller>Chauvin Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02148366</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2003-07-08</ended-marketing-on>
      <dosage-form>Solution / drops</dosage-form>
      <strength/>
      <route>Ophthalmic; Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Benoxil</name>
      <company>Santen</company>
    </international-brand>
    <international-brand>
      <name>Cebesine</name>
      <company>Chauvin Bausch &amp; Lomb</company>
    </international-brand>
    <international-brand>
      <name>Conjuncain</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Dorsacaine</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Lacrimin</name>
      <company>Santen</company>
    </international-brand>
    <international-brand>
      <name>Novesin</name>
      <company>Novartis</company>
    </international-brand>
    <international-brand>
      <name>Novesine</name>
      <company>Novartis</company>
    </international-brand>
    <international-brand>
      <name>Prescaina</name>
      <company>Llorens</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Flurox</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Altafluor</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Altafluor</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Flurox</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Fluorescein Sodium and Benoxinate Hydrochloride</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Fluress</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Fluress Liq Oph</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Minims Benoxinate Hydrochloride 0.4%</name>
      <ingredients>Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Fluorox</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Fluorescein Sodium &amp; Benoxinate Hydrochloride Ophthalmic Solution, USP</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
    <mixture>
      <name>Fluress</name>
      <ingredients>Fluorescein + Oxybuprocaine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Akorn Inc.</name>
      <url>http://www.akorn.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="true" url="">Sola barnes hind</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Fluress eye drops</description>
      <cost currency="USD">2.29</cost>
      <unit>ml</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Aminobenzoates</category>
      <mesh-id>D062365</mesh-id>
    </category>
    <category>
      <category>Anesthetics</category>
      <mesh-id>D000777</mesh-id>
    </category>
    <category>
      <category>Anesthetics for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anesthetics, Local</category>
      <mesh-id>D000779</mesh-id>
    </category>
    <category>
      <category>Antipruritics, Incl. Antihistamines, Anesthetics, Etc.</category>
      <mesh-id/>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzoates</category>
      <mesh-id>D001565</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Cholinesterase substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>para-Aminobenzoates</category>
      <mesh-id>D062366</mesh-id>
    </category>
    <category>
      <category>Peripheral Nervous System Agents</category>
      <mesh-id>D018373</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sensory System Agents</category>
      <mesh-id>D018689</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution / drops</form>
      <route>Ophthalmic; Topical</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01HA02">
      <level code="S01HA">Local anesthetics</level>
      <level code="S01H">LOCAL ANESTHETICS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
    <atc-code code="D04AB03">
      <level code="D04AB">Anesthetics for topical use</level>
      <level code="D04A">ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.</level>
      <level code="D04">ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:16.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00892.pdf?1265922747</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>Hyaluronidase (ovine) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.44e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-(diethylamino)ethyl 4-amino-3-butoxybenzoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>oxybuprocaine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>308.4158</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>308.209992772</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCOC1=C(N)C=CC(=C1)C(=O)OCCN(CC)CC</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C17H28N2O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>CMHHMUWAYWTMGS-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>64.79</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>90.64</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>35.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>19.76</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Very soluble (hydrochloride salt)</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>216.5 °C at 2.00E+00 mm Hg</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.1</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6189</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>309594</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>4633</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505399</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D08319</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4472</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50225499</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164764617</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001231</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Oxybuprocaine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/fluress.htm</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000400</smpdb-id>
      <name>Oxybuprocaine Action Pathway</name>
      <category>drug_action</category>
      <drugs>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00368</drugbank-id>
          <name>Norepinephrine</name>
        </drug>
        <drug>
          <drugbank-id>DB00892</drugbank-id>
          <name>Oxybuprocaine</name>
        </drug>
        <drug>
          <drugbank-id>DB00988</drugbank-id>
          <name>Dopamine</name>
        </drug>
        <drug>
          <drugbank-id>DB01345</drugbank-id>
          <name>Potassium cation</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>Q9Y5Y9</uniprot-id>
        <uniprot-id>Q07699</uniprot-id>
        <uniprot-id>P17787</uniprot-id>
        <uniprot-id>P43681</uniprot-id>
        <uniprot-id>O00555</uniprot-id>
        <uniprot-id>Q02641</uniprot-id>
        <uniprot-id>Q9NY47</uniprot-id>
        <uniprot-id>Q9NZV8</uniprot-id>
        <uniprot-id>Q9NS61</uniprot-id>
        <uniprot-id>P05023</uniprot-id>
        <uniprot-id>P50993</uniprot-id>
        <uniprot-id>P13637</uniprot-id>
        <uniprot-id>Q13733</uniprot-id>
        <uniprot-id>P05026</uniprot-id>
        <uniprot-id>P14415</uniprot-id>
        <uniprot-id>P54709</uniprot-id>
        <uniprot-id>B7ZKV8</uniprot-id>
        <uniprot-id>P54710</uniprot-id>
        <uniprot-id>P01189</uniprot-id>
        <uniprot-id>P01203</uniprot-id>
        <uniprot-id>P16519</uniprot-id>
        <uniprot-id>Q05586</uniprot-id>
        <uniprot-id>Q12879</uniprot-id>
        <uniprot-id>Q8TCU5</uniprot-id>
        <uniprot-id>P35348</uniprot-id>
        <uniprot-id>P08908</uniprot-id>
        <uniprot-id>P23975</uniprot-id>
        <uniprot-id>P31645</uniprot-id>
        <uniprot-id>Q01959</uniprot-id>
        <uniprot-id>P21728</uniprot-id>
        <uniprot-id>P35372</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000177</id>
      <name>Sodium channel protein type 10 subunit alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A5850</ref-id>
            <pubmed-id>19429093</pubmed-id>
            <citation>Hung CH, Wang JJ, Chen YC, Chu CC, Chen YW: Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53. doi: 10.1016/j.neulet.2009.03.018. Epub  2009 Mar 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9Y5Y9" source="Swiss-Prot">
        <name>Sodium channel protein type 10 subunit alpha</name>
        <general-function>Voltage-gated sodium channel activity</general-function>
        <specific-function>Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.</specific-function>
        <gene-name>SCN10A</gene-name>
        <locus>3p22-p21</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>126-149
155-174
188-206
213-232
249-272
374-399
660-684
696-719
728-747
754-773
790-810
865-890
1148-1171
1185-1210
1217-1238
1243-1264
1284-1311
1392-1418
1472-1495
1507-1530
1537-1560
1573-1594
1610-1632
1698-1722</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.77</theoretical-pi>
        <molecular-weight>220623.605</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SCN10A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF117907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4838145</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>585</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>585</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y5Y9</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SCNAA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hPN3</synonym>
          <synonym>Peripheral nerve sodium channel 3</synonym>
          <synonym>PN3</synonym>
          <synonym>Sodium channel protein type X subunit alpha</synonym>
          <synonym>Voltage-gated sodium channel subunit alpha Nav1.8</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016027|Sodium channel protein type 10 subunit alpha
MEFPIGSLETNNFRRFTPESLVEIEKQIAAKQGTKKAREKHREQKDQEEKPRPQLDLKAC
NQLPKFYGELPAELIGEPLEDLDPFYSTHRTFMVLNKGRTISRFSATRALWLFSPFNLIR
RTAIKVSVHSWFSLFITVTILVNCVCMTRTDLPEKIEYVFTVIYTFEALIKILARGFCLN
EFTYLRDPWNWLDFSVITLAYVGTAIDLRGISGLRTFRVLRALKTVSVIPGLKVIVGALI
HSVKKLADVTILTIFCLSVFALVGLQLFKGNLKNKCVKNDMAVNETTNYSSHRKPDIYIN
KRGTSDPLLCGNGSDSGHCPDGYICLKTSDNPDFNYTSFDSFAWAFLSLFRLMTQDSWER
LYQQTLRTSGKIYMIFFVLVIFLGSFYLVNLILAVVTMAYEEQNQATTDEIEAKEKKFQE
ALEMLRKEQEVLAALGIDTTSLHSHNGSPLTSKNASERRHRIKPRVSEGSTEDNKSPRSD
PYNQRRMSFLGLASGKRRASHGSVFHFRSPGRDISLPEGVTDDGVFPGDHESHRGSLLLG
GGAGQQGPLPRSPLPQPSNPDSRHGEDEHQPPPTSELAPGAVDVSAFDAGQKKTFLSAEY
LDEPFRAQRAMSVVSIITSVLEELEESEQKCPPCLTSLSQKYLIWDCCPMWVKLKTILFG
LVTDPFAELTITLCIVVNTIFMAMEHHGMSPTFEAMLQIGNIVFTIFFTAEMVFKIIAFD
PYYYFQKKWNIFDCIIVTVSLLELGVAKKGSLSVLRSFRLLRVFKLAKSWPTLNTLIKII
GNSVGALGNLTIILAIIVFVFALVGKQLLGENYRNNRKNISAPHEDWPRWHMHDFFHSFL
IVFRILCGEWIENMWACMEVGQKSICLILFLTVMVLGNLVVLNLFIALLLNSFSADNLTA
PEDDGEVNNLQVALARIQVFGHRTKQALCSFFSRSCPFPQPKAEPELVVKLPLSSSKAEN
HIAANTARGSSGGLQAPRGPRDEHSDFIANPTVWVSVPIAEGESDLDDLEDDGGEDAQSF
QQEVIPKGQQEQLQQVERCGDHLTPRSPGTGTSSEDLAPSLGETWKDESVPQVPAEGVDD
TSSSEGSTVDCLDPEEILRKIPELADDLEEPDDCFTEGCIRHCPCCKLDTTKSPWDVGWQ
VRKTCYRIVEHSWFESFIIFMILLSSGSLAFEDYYLDQKPTVKALLEYTDRVFTFIFVFE
MLLKWVAYGFKKYFTNAWCWLDFLIVNISLISLTAKILEYSEVAPIKALRTLRALRPLRA
LSRFEGMRVVVDALVGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFWRCINYTDGEFSL
VPLSIVNNKSDCKIQNSTGSFFWVNVKVNFDNVAMGYLALLQVATFKGWMDIMYAAVDSR
EVNMQPKWEDNVYMYLYFVIFIIFGGFFTLNLFVGVIIDNFNQQKKKLGGQDIFMTEEQK
KYYNAMKKLGSKKPQKPIPRPLNKFQGFVFDIVTRQAFDITIMVLICLNMITMMVETDDQ
SEEKTKILGKINQFFVAVFTGECVMKMFALRQYYFTNGWNVFDFIVVVLSIASLIFSAIL
KSLQSYFSPTLFRVIRLARIGRILRLIRAAKGIRTLLFALMMSLPALFNIGLLLFLVMFI
YSIFGMSSFPHVRWEAGIDDMFNFQTFANSMLCLFQITTSAGWDGLLSPILNTGPPYCDP
NLPNSNGTRGDCGSPAVGIIFFTTYIIISFLIMVNMYIAVILENFNVATEESTEPLSEDD
FDMFYETWEKFDPEATQFITFSALSDFADTLSGPLRIPKPNRNILIQMDLPLVPGDKIHC
LDILFAFTKNVLGESGELDSLKANMEEKFMATNLSKSSYEPIATTLRWKQEDISATVIQK
AYRSYVLHRSMALSNTPCVPRAEEEAASLPDEGFVAFTANENCVLPDKSETASATSFPPS
YESVTRGLSDRVNMRTSSSIQNEDEATSMELIAPGP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016028|Sodium channel protein type 10 subunit alpha (SCN10A)
ATGGAATTCCCCATTGGATCCCTCGAAACTAACAACTTCCGTCGCTTTACTCCGGAGTCA
CTGGTGGAGATAGAGAAGCAAATTGCTGCCAAGCAGGGAACAAAGAAAGCCAGAGAGAAG
CATAGGGAGCAGAAGGACCAAGAAGAGAAGCCTCGGCCCCAGCTGGACTTGAAAGCCTGC
AACCAGCTGCCCAAGTTCTATGGTGAGCTCCCAGCAGAACTGATCGGGGAGCCCCTGGAG
GATCTAGATCCGTTCTACAGCACACACCGGACATTTATGGTGCTGAACAAAGGGAGGACC
ATTTCCCGGTTTAGTGCCACTCGGGCCCTGTGGCTATTCAGTCCTTTCAACCTGATCAGA
AGAACGGCCATCAAAGTGTCTGTCCACTCGTGGTTCAGTTTATTTATTACGGTCACTATT
TTGGTTAATTGTGTGTGCATGACCCGAACTGACCTTCCAGAGAAAATTGAATATGTCTTC
ACTGTCATTTACACCTTTGAAGCCTTGATAAAGATACTGGCAAGAGGATTTTGTCTAAAT
GAGTTCACGTACCTGAGAGATCCTTGGAACTGGCTGGATTTTAGCGTCATTACCCTGGCA
TATGTTGGCACAGCAATAGATCTCCGTGGGATCTCAGGCCTGCGGACATTCAGAGTTCTT
AGAGCATTAAAAACAGTTTCTGTGATCCCAGGCCTGAAGGTCATTGTGGGGGCCCTGATT
CACTCAGTGAAGAAACTGGCTGATGTGACCATCCTCACCATCTTCTGCCTAAGTGTTTTT
GCCTTGGTGGGGCTGCAACTCTTCAAGGGCAACCTCAAAAATAAATGTGTCAAGAATGAC
ATGGCTGTCAATGAGACAACCAACTACTCATCTCACAGAAAACCAGATATCTACATAAAT
AAGCGAGGCACTTCTGACCCCTTACTGTGTGGCAATGGATCTGACTCAGGCCACTGCCCT
GATGGTTATATCTGCCTTAAAACTTCTGACAACCCGGATTTTAACTACACCAGCTTTGAT
TCCTTTGCTTGGGCTTTCCTCTCACTGTTCCGCCTCATGACACAGGATTCCTGGGAACGC
CTCTACCAGCAGACCCTGAGGACTTCTGGGAAAATCTATATGATCTTTTTTGTGCTCGTA
ATCTTCCTGGGATCTTTCTACCTGGTCAACTTGATCTTGGCTGTAGTCACCATGGCGTAT
GAGGAGCAGAACCAGGCAACCACTGATGAAATTGAAGCAAAGGAGAAGAAGTTCCAGGAG
GCCCTCGAGATGCTCCGGAAGGAGCAGGAGGTGCTAGCAGCACTAGGGATTGACACAACC
TCTCTCCACTCCCACAATGGATCACCTTTAACCTCCAAAAATGCCAGTGAGAGAAGGCAT
AGAATAAAGCCAAGAGTGTCAGAGGGCTCCACAGAAGACAACAAATCACCCCGCTCTGAT
CCTTACAACCAGCGCAGGATGTCTTTTCTAGGCCTCGCCTCTGGAAAACGCCGGGCTAGT
CATGGCAGTGTGTTCCATTTCCGGTCCCCTGGCCGAGATATCTCACTCCCTGAGGGAGTC
ACAGATGATGGAGTCTTTCCTGGAGACCACGAAAGCCATCGGGGCTCTCTGCTGCTGGGT
GGGGGTGCTGGCCAGCAAGGCCCCCTCCCTAGAAGCCCTCTTCCTCAACCCAGCAACCCT
GACTCCAGGCATGGAGAAGATGAACACCAACCGCCGCCCACTAGTGAGCTTGCCCCTGGA
GCTGTCGATGTCTCGGCATTCGATGCAGGACAAAAGAAGACTTTCTTGTCAGCAGAATAC
TTAGATGAACCTTTCCGGGCCCAAAGGGCAATGAGTGTTGTCAGTATCATAACCTCCGTC
CTTGAGGAACTCGAGGAGTCTGAACAGAAGTGCCCACCCTGCTTGACCAGCTTGTCTCAG
AAGTATCTGATCTGGGATTGCTGCCCCATGTGGGTGAAGCTCAAGACAATTCTCTTTGGG
CTTGTGACGGATCCCTTTGCAGAGCTCACCATCACCTTGTGCATCGTGGTGAACACCATC
TTCATGGCCATGGAGCACCATGGCATGAGCCCTACCTTCGAAGCCATGCTCCAGATAGGC
AACATCGTCTTTACCATATTTTTTACTGCTGAAATGGTCTTCAAAATCATTGCCTTCGAC
CCATACTATTATTTCCAGAAGAAGTGGAATATCTTTGACTGCATCATCGTCACTGTGAGT
CTGCTAGAGCTGGGCGTGGCCAAGAAGGGAAGCCTGTCTGTGCTGCGGAGCTTCCGCTTG
CTGCGCGTATTCAAGCTGGCCAAATCCTGGCCCACCTTAAACACACTCATCAAGATCATC
GGAAACTCAGTGGGGGCACTGGGGAACCTCACCATCATCCTGGCCATCATTGTCTTTGTC
TTTGCTCTGGTTGGCAAGCAGCTCCTAGGGGAAAACTACCGTAACAACCGAAAAAATATC
TCCGCGCCCCATGAAGACTGGCCCCGCTGGCACATGCACGACTTCTTCCACTCTTTCCTC
ATTGTCTTCCGTATCCTCTGTGGAGAGTGGATTGAGAACATGTGGGCCTGCATGGAAGTT
GGCCAAAAATCCATATGCCTCATCCTTTTCTTGACGGTGATGGTGCTAGGGAACCTGGTG
GTGCTTAACCTGTTCATCGCCCTGCTATTGAACTCTTTCAGTGCTGACAACCTCACAGCC
CCGGAGGACGATGGGGAGGTGAACAACCTGCAGGTGGCCCTGGCACGGATCCAGGTCTTT
GGCCATCGTACCAAACAGGCTCTTTGCAGCTTCTTCAGCAGGTCCTGCCCATTCCCCCAG
CCCAAGGCAGAGCCTGAGCTGGTGGTGAAACTCCCACTCTCCAGCTCCAAGGCTGAGAAC
CACATTGCTGCCAACACTGCCAGGGGGAGCTCTGGAGGGCTCCAAGCTCCCAGAGGCCCC
AGGGATGAGCACAGTGACTTCATCGCTAATCCGACTGTGTGGGTCTCTGTGCCCATTGCT
GAGGGTGAATCTGATCTTGATGACTTGGAGGATGATGGTGGGGAAGATGCTCAGAGCTTC
CAGCAGGAAGTGATCCCCAAAGGACAGGAGCAGCTGCAGCAAGTCGAGAGGTGTGGGGAC
CACCTGACACCCAGGAGCCCAGGCACTGGAACATCTTCTGAGGACCTGGCTCCATCCCTG
GGTGAGACGTGGAAAGATGAGTCTGTTCCTCAGGTCCCTGCTGAGGGAGTGGACGACACA
AGCTCCTCTGAGGGCAGCACGGTGGACTGCCTAGATCCTGAGGAAATCCTGAGGAAGATC
CCTGAGCTGGCAGATGACCTGGAAGAACCAGATGACTGCTTCACAGAAGGATGCATTCGC
CACTGTCCCTGCTGCAAACTGGATACCACCAAGAGTCCATGGGATGTGGGCTGGCAGGTG
CGCAAGACTTGCTACCGTATCGTGGAGCACAGCTGGTTTGAGAGCTTCATCATCTTCATG
ATCCTGCTCAGCAGTGGATCTCTGGCCTTTGAAGACTATTACCTGGACCAGAAGCCCACG
GTGAAAGCTTTGCTGGAGTACACTGACAGGGTCTTCACCTTTATCTTTGTGTTCGAGATG
CTGCTTAAGTGGGTGGCCTATGGCTTCAAAAAGTACTTCACCAATGCCTGGTGCTGGCTG
GACTTCCTCATTGTGAATATCTCACTGATAAGTCTCACAGCGAAGATTCTGGAATATTCT
GAAGTGGCTCCCATCAAAGCCCTTCGAACCCTTCGCGCTCTGCGGCCACTGCGGGCTCTT
TCTCGATTTGAAGGCATGCGGGTGGTGGTGGATGCCCTGGTGGGCGCCATCCCATCCATC
ATGAATGTCCTCCTCGTCTGCCTCATCTTCTGGCTCATCTTCAGCATCATGGGTGTGAAC
CTCTTCGCAGGGAAGTTTTGGAGGTGCATCAACTATACCGATGGAGAGTTTTCCCTTGTA
CCTTTGTCGATTGTGAATAACAAGTCTGACTGCAAGATTCAAAACTCCACTGGCAGCTTC
TTCTGGGTCAATGTGAAAGTCAACTTTGATAATGTTGCAATGGGTTACCTTGCACTTCTG
CAGGTGGCAACCTTTAAAGGCTGGATGGACATTATGTATGCAGCTGTTGATTCCCGGGAG
GTCAACATGCAACCCAAGTGGGAGGACAACGTGTACATGTATTTGTACTTTGTCATCTTC
ATCATTTTTGGAGGCTTCTTCACACTGAATCTCTTTGTTGGGGTCATAATTGACAACTTC
AATCAACAGAAAAAAAAGTTAGGGGGCCAGGACATCTTCATGACAGAGGAGCAGAAGAAA
TACTACAATGCCATGAAGAAGTTGGGCTCCAAGAAGCCCCAGAAGCCCATCCCACGGCCC
CTGAACAAGTTCCAGGGTTTTGTCTTTGACATCGTGACCAGACAAGCTTTTGACATCACC
ATCATGGTCCTCATCTGCCTCAACATGATCACCATGATGGTGGAGACTGATGACCAAAGT
GAAGAAAAGACGAAAATTCTGGGCAAAATCAACCAGTTCTTTGTGGCCGTCTTCACAGGC
GAATGTGTCATGAAGATGTTCGCTTTGAGGCAGTACTACTTCACAAATGGCTGGAATGTG
TTTGACTTCATTGTGGTGGTTCTCTCCATTGCGAGCCTGATTTTTTCTGCAATTCTTAAG
TCACTTCAAAGTTACTTCTCCCCAACGCTCTTCAGAGTCATCCGCCTGGCCCGAATTGGC
CGCATCCTCAGACTGATCCGAGCGGCCAAGGGGATCCGCACACTGCTCTTTGCCCTCATG
ATGTCCCTGCCTGCCCTCTTCAACATCGGGCTGTTGCTATTCCTTGTCATGTTCATCTAC
TCTATCTTCGGTATGTCCAGCTTTCCCCATGTGAGGTGGGAGGCTGGCATCGACGACATG
TTCAACTTCCAGACCTTCGCCAACAGCATGCTGTGCCTCTTCCAGATTACCACGTCGGCC
GGCTGGGATGGCCTCCTCAGCCCCATCCTCAACACAGGGCCCCCCTACTGTGACCCCAAT
CTGCCCAACAGCAATGGCACCAGAGGGGACTGTGGGAGCCCAGCCGTAGGCATCATCTTC
TTCACCACCTACATCATCATCTCCTTCCTCATCGTGGTCAACATGTACATTGCAGTGATT
CTGGAGAACTTCAATGTGGCCACGGAGGAGAGCACTGAGCCCCTGAGTGAGGACGACTTT
GACATGTTCTATGAGACCTGGGAGAAGTTTGACCCAGAGGCCACTCAGTTTATTACCTTT
TCTGCTCTCTCGGACTTTGCAGACACTCTCTCTGGTCCCCTGAGAATCCCAAAACCCAAT
CGAAATATACTGATCCAGATGGACCTGCCTTTGGTCCCTGGAGATAAGATCCACTGCTTG
GACATCCTTTTTGCTTTCACCAAGAATGTCCTAGGAGAATCCGGGGAGTTGGATTCTCTG
AAGGCAAATATGGAGGAGAAGTTTATGGCAACTAATCTTTCAAAATCATCCTATGAACCA
ATAGCAACCACTCTCCGATGGAAGCAAGAAGACATTTCAGCCACTGTCATTCAAAAGGCC
TATCGGAGCTATGTGCTGCACCGCTCCATGGCACTCTCTAACACCCCATGTGTGCCCAGA
GCTGAGGAGGAGGCTGCATCACTCCCAGATGAAGGTTTTGTTGCATTCACAGCAAATGAA
AATTGTGTACTCCCAGACAAATCTGAAACTGCTTCTGCCACATCATTCCCACCGTCCTAT
GAGAGTGTCACTAGAGGCCTTAGTGATAGAGTCAACATGAGGACATCTAGCTCAATACAA
AATGAAGATGAAGCCACCAGTATGGAGCTGATTGCCCCTGGGCCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF06512</identifier>
            <name>Na_trans_assoc</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>clathrin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>voltage-gated sodium channel complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ion channel binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated sodium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>AV node cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bundle of His cell action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane depolarization during action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuronal action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>odontogenesis of dentin-containing tooth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of atrial cardiac muscle cell membrane depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium ion transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="1">
      <id>BE0002180</id>
      <name>Cholinesterase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17773</ref-id>
            <pubmed-id>4069587</pubmed-id>
            <citation>Draeger J, Schloot W, Wirt H: Interindividual differences of corneal sensitivity. Genetic aspects. Ophthalmic Paediatr Genet. 1985 Aug;6(1-2):291-5.</citation>
          </article>
          <article>
            <ref-id>A17774</ref-id>
            <pubmed-id>6621359</pubmed-id>
            <citation>Dubbels R, Schloot W: Studies on the metabolism of benoxinate by human pseudocholinesterase. Metab Pediatr Syst Ophthalmol. 1983;7(1):37-43.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P06276" source="Swiss-Prot">
        <name>Cholinesterase</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.</specific-function>
        <gene-name>BCHE</gene-name>
        <locus>3q26.1-q26.2</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-28</signal-regions>
        <theoretical-pi>7.47</theoretical-pi>
        <molecular-weight>68417.575</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:983</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>BCHE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M32391</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1311630</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2471</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06276</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CHLE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.8</synonym>
          <synonym>Acylcholine acylhydrolase</synonym>
          <synonym>Butyrylcholine esterase</synonym>
          <synonym>CHE1</synonym>
          <synonym>Choline esterase II</synonym>
          <synonym>Pseudocholinesterase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016706|Cholinesterase
MHSKVTIICIRFLFWFLLLCMLIGKSHTEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIP
YAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDC
LYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALG
FLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPG
SHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEI
LLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVY
GAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDV
VGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLER
RDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMT
KLRAQQCRFWTSFFPKVLEMTGNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYTSKKESCV
GL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016707|Cholinesterase (BCHE)
ATGCATAGCAAAGTCACAATCATATGCATCAGATTTCTCTTTTGGTTTCTTTTGCTCTGC
ATGCTTATTGGGAAGTCACATACTGAAGATGACATCATAATTGCAACAAAGAATGGAAAA
GTCAGAGGGATGAACTTGACAGTTTTTGGTGGCACGGTAACAGCCTTTCTTGGAATTCCC
TATGCACAGCCACCTCTTGGTAGACTTCGATTCAAAAAGCCACAGTCTCTGACCAAGTGG
TCTGATATTTGGAATGCCACAAAATATGCAAATTCTTGCTGTCAGAACATAGATCAAAGT
TTTCCAGGCTTCCATGGATCAGAGATGTGGAACCCAAACACTGACCTCAGTGAAGACTGT
TTATATCTAAATGTATGGATTCCAGCACCTAAACCAAAAAATGCCACTGTATTGATATGG
ATTTATGGTGGTGGTTTTCAAACTGGAACATCATCTTTACATGTTTATGATGGCAAGTTT
CTGGCTCGGGTTGAAAGAGTTATTGTAGTGTCAATGAACTATAGGGTGGGTGCCCTAGGA
TTCTTAGCTTTGCCAGGAAATCCTGAGGCTCCAGGGAACATGGGTTTATTTGATCAACAG
TTGGCTCTTCAGTGGGTTCAAAAAAATATAGCAGCCTTTGGTGGAAATCCTAAAAGTGTA
ACTCTCTTTGGAGAAAGTGCAGGAGCAGCTTCAGTTAGCCTGCATTTGCTTTCTCCTGGA
AGCCATTCATTGTTCACCAGAGCCATTCTGCAAAGTGGATCCTTTAATGCTCCTTGGGCG
GTAACATCTCTTTATGAAGCTAGGAACAGAACGTTGAACTTAGCTAAATTGACTGGTTGC
TCTAGAGAGAATGAGACTGAAATAATCAAGTGTCTTAGAAATAAAGATCCCCAAGAAATT
CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG
ACCGTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT
AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT
GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA
GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT
TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT
GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG
GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA
TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA
AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGGTGGGCA
AATTTTGCAAAATATGGGAATCCAAATGAGACTCAGAACAATAGCACAAGCTGGCCTGTC
TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG
AAACTACGTGCTCAACAATGTCGATTCTGGACATCATTTTTTCCAAAAGTCTTGGAAATG
ACAGGAAATATTGATGAAGCAGAATGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT
TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG
GGTCTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
          <pfam>
            <identifier>PF08674</identifier>
            <name>AChE_tetra</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope lumen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>catalytic activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>choline binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cholinesterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acetylcholine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>choline metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cocaine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuroblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to alkaloid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to folic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>